Comparative transcriptomic profiling of peripheral blood mononuclear cells (PBMCs) isolated from patients in secondary prevention of CVD taking placebo, grape extract or resveratrol-enriched grape extract

We used Affymetrix microarrays to investigate gene expression changes in PBMCs isolated from male patients ongoing secondary prevention of CVD to determine significant modulatory effects that may have been induced by the intake of an initial dose of 8 mg of resveratrol-enriched grape extract for 6 months and then, 16 mg for a further 6 months. The aim of this work was to determine whether the daily intake of dietary levels of resveratrol (RES) for a total of 12 months exerted any modulatory effects, at the level of gene expression, in PBMCs isolated from patients in secondary prevention of CVD. Male patients were divided in 3 groups: placebo (A), grape extract (B) and resveratrol-enriched grape extract (C). Total RNA was extracted from isolated PBMCs belonging to a total of 18 diabetic male patients (6 from each group) in 3 time points (at day 0, after 6 months and after 12 months) to compare differential gene expression between the groups. Differential gene expression after 6 and 12 months of the study for each group: placebo (A), grape extract (B) and resveratrol-enriched grape extract (C)

本研究采用Affymetrix基因芯片（Affymetrix microarrays），对正在接受心血管疾病（Cardiovascular Disease, CVD）二级预防的男性患者的分离外周血单个核细胞（Peripheral Blood Mononuclear Cells, PBMC）进行基因表达变化分析，以探究初始剂量为8 mg的富含白藜芦醇葡萄提取物、连续服用6个月后调整为16 mg、再持续服用6个月所诱导的显著调控效应。本研究的核心目标为明确：每日摄入膳食剂量的白藜芦醇（Resveratrol, RES）、总干预时长共计12个月，是否会对接受CVD二级预防的患者的分离PBMC的基因表达水平产生调控作用。本研究共纳入18名男性糖尿病患者，按干预方案分为3组：安慰剂组（A组）、普通葡萄提取物组（B组）与富含白藜芦醇的葡萄提取物组（C组），每组各6人。研究分别在给药第0天、干预6个月后、干预12个月后三个时间节点采集各组患者的PBMC并提取总RNA，以比较各组间的差异基因表达情况。本研究同时针对上述三组，分别分析其在干预6个月、12个月后的差异基因表达特征。